COVID-19 Therapeutics and Treatment

Oral Antiviral

Paxlovid (Nirmatrelvir)

Click here to request a covid-19 treatment consult

COVID-19 Antibody Prevention

Evusheld

What is evusheld?

The FDA has issued an EUA for the unapproved product of EVUSHELD for pre-exposure prophylaxis of COVID-19 in
adults and pediatric patients (12 years of age or older and weighing at least 40 kg):

*Who are currently NOT infected with COVID-19 and have not had a known exposure to an individual with COVID-19 AND *Has moderate to severe immune compromise due to a medical condition or immunosuppressive medication or treatments and may not mount an adequate immune response to COVID-19
vaccination

OR

For those whom vaccination with
any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to the vaccine or vaccine components.

- Administered as two consecutive IM shots.

Medical conditions that may result in moderate to severe immune compromise and an inadequate response to COVID-19 vaccination include by are not limited to:

-Active treatment for solid tumor
and hematologic malignancies

-Receipt of solid-organ transplant and taking immunosuppressive therapy

- Receipt of CAR-T-cell or hematopoietic stem cell transplant

- Moderate or severe primary immunodeficiency

- Advanced or untreated HIV infection

- Active treatment with high-dose corticosteroids, or other drugs that may suppress the immune response

Limitations of use:

Not authorized for use in individuals:

- For treatment of COVID-19

- For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone with COVID-19.

- Individuals who have received COVID-19 vaccine, EVUSHELD should be administered at least 2 weeks after vaccination.

- Pre-exposure prophylaxis is not a substitute for vaccination in individuals from whom COVID-19 vaccination is recommended.

Paxlovid - The Process:

* Complete the form above to determine if you are eligible for treatment

* If you are NOT eligible, our form will let you know.

* If you ARE eligible, you will be able to book a COVID-19 Consultation. There is a non-refundable cost of $49.99 associated with the consult.

* Our pharmacist staff will review your request and then contact you via phone to confirm appropriateness of therapy, and then prescribe treatment (if appropriate)

WHAT IS A MONOCLONAL ANTIBODY?


Monoclonal antibodies (mAb) are a new treatment option for COVID-19 which has been given emergency use authorization (EUA) by the FDA. Monoclonal antibodies are designed in a laboratory to do what our own natural antibodies do, only better. Antibodies are what our body makes on its own to identify and fight infection. The reason we might require treatment with monoclonal antibodies, or mAbs, is that our body may not recognize this new virus SARS-Cov-2 which causes COVID-19. Treatment with mAbs requires direct administration to patients via IV infusion or injection under the skin (subcutaneously). When receiving treatment with mAbs, our bodies can very quickly recognize and fight COVID-19 infection. This is why mAb treatment may help recently exposed or infected patients who are at high risk for serious symptoms or having to stay in the hospital.

mAb treatment for COVID-19 is different from a COVID-19 vaccine. A vaccine causes your body’s natural immune response to turn on, but the process of asking your body to make antibodies or biological markers to identify a certain infection can take weeks. Some vaccines for COVID-19 require two shots, so your body can develop its own immune response to the disease, and these vaccines are highly effective. But if you already have the virus, mAb treatment quickly gives your body the antibodies it needs to protect itself. (1)

Monoclonal Antibodies

COVID-19 Antibody Treatment (REGEN-COV™)

The FDA has removed this product from the market due to the lack of effectiveness against the Omicron variant. This is no longer available any where in the country.

Works Cited

(1). Assistant Secretary for
Public Affairs (ASPA). “Monoclonal Antibodies for High-Risk COVID-19 Positive
Patients.” CombatCOVID.hhs.gov, 24 Aug. 2021,
https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients.